Skip to main content

Table 3 Hazard ratios for reaching remission/low disease activity associated with overlapping SS according to the stratification

From: Overlapping Sjogren’s syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019

 RemissionRemission/LDA
DAS28-ESRDAS28-CRPSDAICDAIBooleanDAS28-ESRDAS28-CRPSDAICDAI
Unmatched cohort
 Age0.74 (0.65, 0.84)0.93 (0.84, 1.04)0.94 (0.82, 1.07)0.90 (0.78, 1.03)0.96 (0.84, 1.10)0.87 (0.79, 0.97)*0.94 (0.85, 1.03)0.92 (0.84, 1.01)0.91 (0.83, 1.00)
 RF/ACPA0.68 (0.62, 0.75)0.80 (0.74, 0.87)0.82 (0.74, 0.91)0.77 (0.70, 0.86)0.83 (0.75, 0.92)0.76 (0.70, 0.82)0.80 (0.74, 0.86)0.79 (0.73, 0.85)0.78 (0.73, 0.84)
 RA duration1.45 (0.95, 2.22)1.45 (0.99, 2.14)1.18 (0.68, 2.05)0.88 (0.46, 1.68)1.13 (0.65, 1.97)1.44 (1.00, 2.08)1.48 (1.06, 2.07)1.39 (0.99, 1.95)1.40 (1.00, 1.96)
  Duration ≥ 6 months0.67 (0.61, 0.74)0.80 (0.74, 0.87)0.82 (0.74, 0.91)0.77 (0.70, 0.86)0.83 (0.75, 0.92)0.76 (0.70, 0.82)0.80 (0.74, 0.86)0.79 (0.73, 0.85)0.78 (0.73, 0.84)
 DAS28-CRP at 1st visit0.64 (0.58, 0.70)0.76 (0.70, 0.82)0.76 (0.69, 0.84)0.71 (0.64, 0.79)0.77 (0.70, 0.85)0.73 (0.67, 0.79)0.78 (0.72, 0.84)0.77 (0.71, 0.82)0.76 (0.71, 0.82)
Matched cohort
 Age0.81 (0.67, 0.98)*0.85 (0.73, 0.99)*0.91 (0.74, 1.11)0.91 (0.74, 1.13)0.91 (0.74, 1.11)0.86 (0.73, 1.00)0.86 (0.75, 0.99)*0.82 (0.71, 0.95)*0.83 (0.72, 0.95)*
 RF/ACPA0.71 (0.62, 0.82)0.74 (0.66, 0.83)0.82 (0.70, 0.94)*0.78 (0.67, 0.91)0.80 (0.69, 0.93)0.73 (0.65, 0.82)0.76 (0.68, 0.84)0.74 (0.66, 0.82)0.74 (0.66, 0.82)
 RA duration2.51 (1.36, 4.61)1.93 (1.15, 3.26)*1.74 (0.81, 3.73)1.18 (0.51, 2.73)1.46 (0.70, 3.04)2.07 (1.26, 3.40)1.77 (1.14, 2.74)*1.61 (1.04, 2.47)*1.64 (1.06, 2.53)*
  Duration ≥ 6 months0.70 (0.61, 0.81)0.74 (0.66, 0.83)0.82 (0.71, 0.95)*0.78 (0.67, 0.92)0.81 (0.69, 0.94)*0.73 (0.65, 0.82)0.76 (0.68, 0.84)0.74 (0.66, 0.82)0.74 (0.66, 0.82)
 DAS28-CRP at 1st visit0.70 (0.61, 0.81)0.73 (0.65, 0.82)0.78 (0.67, 0.90)0.75 (0.64, 0.87)0.77 (0.66, 0.89)0.71 (0.64, 0.80)0.73 (0.65, 0.81)0.71 (0.64, 0.79)0.71 (0.64, 0.79)
Trimmed cohort
 Age0.80 (0.66, 0.98)*0.81 (0.69, 0.95)*0.90 (0.73, 1.11)0.87 (0.70, 1.08)0.90 (0.73, 1.11)0.83 (0.71, 0.98)*0.83 (0.72, 0.97)*0.80 (0.69, 0.93)0.81 (0.70, 0.94)
 RF/ACPA0.74 (0.64, 0.85)0.74 (0.66, 0.83)0.83 (0.72, 0.97)*0.78 (0.67, 0.91)0.82 (0.70, 0.95)*0.74 (0.66, 0.83)0.75 (0.68, 0.84)0.74 (0.66, 0.82)0.74 (0.66, 0.82)*
 RA duration2.49 (1.35, 4.59)1.91 (1.13, 3.22)*1.72 (0.80, 3.70)1.16 (0.50, 2.70)1.45 (0.69, 3.01)2.05 (1.25, 3.37)*1.85 (1.19, 2.87)*1.68 (1.08, 2.59)*1.71 (1.10, 2.65)
  Duration ≥ 6 months0.72 (0.63, 0.83)0.74 (0.65, 0.83)0.83 (0.72, 0.97)*0.79 (0.67, 0.92)0.82 (0.71, 0.96)*0.74 (0.66, 0.83)0.75 (0.68, 0.84)0.73 (0.66, 0.82)0.73 (0.66, 0.82)
 DAS28-CRP at 1st visit0.71 (0.62, 0.82)0.72 (0.64, 0.81)0.79 (0.68, 0.91)0.74 (0.63, 0.86)0.77 (0.66, 0.90)0.71 (0.64, 0.80)0.72 (0.65, 0.80)0.71 (0.64, 0.79)0.71 (0.64, 0.79)
  1. Values are presented as stratified hazard ratio (95% CI) for reaching remission and/or low disease activity based on DAS28-ESR, DAS28-CRP, SDAI, and CDAI in RA patients according to age, RF/ACPA status, RA duration, and DAS28-CRP at 1st visit
  2. *Statistically significant at the level of 0.05
  3. Statistically significant at the level of 0.01